股本结构
单位：万股
| 公告日期 | 2026-08-13 | 2026-08-13 | 2026-05-14 | 2026-04-30 | 2026-05-14 | 2026-03-19 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1485.24 | 1420.61 | 1280.33 | 1200.76 | 1187.33 | 1164.83 |
| 普通股本 | 1485.24 | 1420.61 | 1280.33 | 1200.76 | 1187.33 | 1164.83 |
| 优先股 | 未披露 | 2.11 | 未披露 | 2.23 | 2.24 | 2.24 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-11 | 2026-06-30 | 2026-05-13 | 2026-04-21 | 2026-03-31 | 2025-12-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-13 | 1485.24 | 未披露 | 定期报告 | 2026-08-11 |
| 2026-08-13 | 1420.61 | 2.11 |
更多>>
From April 1,2026 to June 30,2026
Conversion of convertible notes into Common
Conversion of Series B-2 Preferred into Common
Conversion of Series B-3 Preferred into Common
Conversion of Series C Preferred into Common
|
2026-06-30 |
| 2026-05-14 | 1280.33 | 未披露 | 定期报告 | 2026-05-13 |
| 2026-04-30 | 1200.76 | 2.23 | 定期报告 | 2026-04-21 |
| 2026-05-14 | 1187.33 | 2.24 |
更多>>
From January 1,2026 to March 31,2026
Issuance of shares for restricted stock units
|
2026-03-31 |
| 2026-03-19 | 1164.83 | 2.24 |
更多>>
From December 31, 2024 to December 31, 2025
Issuance of Series C Preferred, net of offering costs
Issuance of Series D Preferred, net of receivable from shareholder
Conversion of Series B-2 and B-3 Preferred into common stock
Conversion of Series C Preferred into common stock
Issuance of shares for restricted stock units
|
2025-12-31 |
| 2025-11-12 | 1164.83 | 1.99 |
更多>>
From June 30,2025 to September 30,2025
Issuance of Series C Preferred
Issuance of Series D Preferred, net of receivable from shareholder
Conversion of Series B-2 Preferred into Common
Conversion of Series C Preferred into Common
Release of Restricted Stock Units
|
2025-09-30 |
| 2025-08-13 | 1066.84 | 未披露 | 定期报告 | 2025-08-12 |
| 2025-08-05 | 1013.86 | 2.08 | 定期报告 | 2025-07-18 |
| 2025-07-16 | 1013.86 | 2.08 | 定期报告 | 2025-07-15 |
| 2025-08-13 | 1013.86 | 0.92 |
更多>>
From April 1, 2025 to June 30, 2025
Conversion of Series B-2 Preferred into Common
Conversion of Series B-3 Preferred into Common
|
2025-06-30 |
| 2025-04-30 | 944.62 | 0.97 | 定期报告 | 2025-04-22 |
| 2025-03-20 | 887.39 | 1.01 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of Series B-3 Preferred upon exercise of warrants
Exercise of pre-funded warrants
Conversion of Series B-1 Preferred (mezzanine) into Series B-2 Preferred and common stock
Issuance of shares for restricted stock units
Conversion of Series B-2 and B-3 Preferred into common stock
|
2024-12-31 |
| 2024-11-14 | 774.92 | 未披露 | 定期报告 | 2024-11-12 |
| 2024-11-14 | 652.98 | 1.18 |
更多>>
From July 1, 2024 to September 30, 2024
Conversion of Series B Preferred into Common
|
2024-09-30 |
| 2024-08-14 | 554.35 | 未披露 | 定期报告 | 2024-08-12 |
| 2024-08-14 | 509.42 | 1.28 |
更多>>
From April 1, 2024 to June 30, 2024
Issuance of Series B-3 upon exercise of warrants
Issuance of RSUs
|
2024-06-30 |
| 2024-03-21 | 508.94 | 0.48 | 定期报告 | 2024-03-18 |
| 2024-03-15 | 508.94 | 未披露 | 定期报告 | 2024-02-22 |
| 2024-01-17 | 168.46 | 未披露 | 定期报告 | 2024-01-10 |
| 2024-03-15 | 151.76 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Issuance of shares in reverse stock split (for fractional shares)
Issuance of common stock and warrants, under registered public offering
Issuance of shares for vested restricted stock units
|
2023-12-31 |
| 2023-11-01 | 151.76 | 未披露 |
更多>>
Securities offered 150,000 shares by the company
|
2023-11-02 |
| 2023-11-09 | 136.76 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of shares in reverse stock split (for fractional shares)
|
2023-09-30 |
| 2023-08-11 | 136.76 | 未披露 | 定期报告 | 2023-08-09 |
| 2023-07-03 | 133.50 | 未披露 |
更多>>
Biofrontera Inc. announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 that will become effective after the close of trading at 11:59 p.m. July 3, 2023.
|
2023-07-05 |
| 2023-03-13 | 2669.90 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Exercise of pre-funded warrants
Exercise of PIPE warrants
Issuance of common stock and warrants under private placement, net of negligible issuance costs
Issuance of shares for vested restricted stock units
Issuance of common stock in exchange for investments in equity securities
|
2022-12-31 |
| 2022-11-15 | 2669.90 | 未披露 | 定期报告 | 2022-11-02 |
| 2022-11-14 | 2355.10 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Exercise of pre-funded warrants
Exercise of PIPE warrants
Issuance of shares for vested restricted stock units
|
2022-09-30 |
| 2022-08-12 | 2355.10 | 未披露 | 定期报告 | 2022-08-11 |
| 2022-08-12 | 1901.14 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock and warrants under private placement, net of issuance costs
Issuance of shares for vested restricted stock units
|
2022-06-30 |
| 2022-06-07 | 1895.47 | 未披露 | 定期报告 | 2022-06-06 |
| 2022-05-13 | 1710.47 | 未披露 | 定期报告 | 2022-03-31 |
| 2021-12-29 | 1710.47 | 未披露 | 定期报告 | 2021-12-28 |
| 2021-12-23 | 1505.60 | 未披露 | 定期报告 | 2021-12-20 |
| 2021-11-03 | 1214.00 | 未披露 |
更多>>
1.The underwriters exercised in full their option to purchase up to an additional 540,000 Warrants to cover over-allotments.
2.The number of shares of common stock to be outstanding after this offering is based on 11,600,000 shares of common stock outstanding as of October 29, 2021
|
2021-11-02 |
| 2021-11-01 | 1160.00 | 未披露 |
更多>>
1.Securities offered by company 3,600,000 units.
2.The number of shares of common stock to be outstanding after this offering is based on 8,000,000 shares of common stock outstanding as of June 30, 2021
|
2021-10-29 |
From April 1,2026 to June 30,2026
Conversion of convertible notes into Common
Conversion of Series B-2 Preferred into Common
Conversion of Series B-3 Preferred into Common
Conversion of Series C Preferred into Common
From January 1,2026 to March 31,2026
Issuance of shares for restricted stock units
From December 31, 2024 to December 31, 2025
Issuance of Series C Preferred, net of offering costs
Issuance of Series D Preferred, net of receivable from shareholder
Conversion of Series B-2 and B-3 Preferred into common stock
Conversion of Series C Preferred into common stock
Issuance of shares for restricted stock units
From June 30,2025 to September 30,2025
Issuance of Series C Preferred
Issuance of Series D Preferred, net of receivable from shareholder
Conversion of Series B-2 Preferred into Common
Conversion of Series C Preferred into Common
Release of Restricted Stock Units
From April 1, 2025 to June 30, 2025
Conversion of Series B-2 Preferred into Common
Conversion of Series B-3 Preferred into Common
From December 31, 2023 to December 31, 2024
Issuance of Series B-3 Preferred upon exercise of warrants
Exercise of pre-funded warrants
Conversion of Series B-1 Preferred (mezzanine) into Series B-2 Preferred and common stock
Issuance of shares for restricted stock units
Conversion of Series B-2 and B-3 Preferred into common stock
From July 1, 2024 to September 30, 2024
Conversion of Series B Preferred into Common
From April 1, 2024 to June 30, 2024
Issuance of Series B-3 upon exercise of warrants
Issuance of RSUs
From December 31, 2022 to December 31, 2023
Issuance of shares in reverse stock split (for fractional shares)
Issuance of common stock and warrants, under registered public offering
Issuance of shares for vested restricted stock units
Securities offered 150,000 shares by the company
From June 30, 2023 to September 30, 2023
Issuance of shares in reverse stock split (for fractional shares)
Biofrontera Inc. announces that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20 that will become effective after the close of trading at 11:59 p.m. July 3, 2023.
From December 31, 2021 to December 31, 2022
Exercise of pre-funded warrants
Exercise of PIPE warrants
Issuance of common stock and warrants under private placement, net of negligible issuance costs
Issuance of shares for vested restricted stock units
Issuance of common stock in exchange for investments in equity securities
From June 30, 2022 to September 30, 2022
Exercise of pre-funded warrants
Exercise of PIPE warrants
Issuance of shares for vested restricted stock units
From March 31, 2022 to June 30, 2022
Issuance of common stock and warrants under private placement, net of issuance costs
Issuance of shares for vested restricted stock units
1.The underwriters exercised in full their option to purchase up to an additional 540,000 Warrants to cover over-allotments.
2.The number of shares of common stock to be outstanding after this offering is based on 11,600,000 shares of common stock outstanding as of October 29, 2021
1.Securities offered by company 3,600,000 units.
2.The number of shares of common stock to be outstanding after this offering is based on 8,000,000 shares of common stock outstanding as of June 30, 2021